secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001770787-22-000026
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained
--------------------------------------------------------------------------------

- Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.
- Net loss $42.4M vs $11.6M in Q1 2021; operating loss $41.7M including $26.0M stock-based comp.
- Operating expenses rose 32% to $130.8M driven by higher personnel, R&D, and infrastructure costs.
- Cash and marketable securities $539.3M as of March 31, 2022.
- Full-year 2022 revenue guidance maintained at $600M-$630M, implying 22-28% growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/0001770787-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/txg-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001770787-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer